These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9103530)

  • 1. The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
    Asin KE; Domino EF; Nikkel A; Shiosaki K
    J Pharmacol Exp Ther; 1997 Apr; 281(1):454-9. PubMed ID: 9103530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R; Bédard PJ; Britton DR; Shiosaki K
    Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.
    Shiosaki K; Asin KE; Britton DR; Giardina WJ; Bednarz L; Mahan L; Mikusa J; Nikkel A; Wismer C
    Eur J Pharmacol; 1996 Dec; 317(2-3):183-90. PubMed ID: 8997599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).
    Michaelides MR; Hong Y; DiDomenico S; Asin KE; Britton DR; Lin CW; Williams M; Shiosaki K
    J Med Chem; 1995 Sep; 38(18):3445-7. PubMed ID: 7658429
    [No Abstract]   [Full Text] [Related]  

  • 6. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
    Gulwadi AG; Korpinen CD; Mailman RB; Nichols DE; Sit SY; Taber MT
    J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trihexyphenidyl interactions with the dopamine D1-selective receptor agonist SKF-82958 and the D2-selective receptor agonist N-0923 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Ni L
    J Pharmacol Exp Ther; 1998 Jan; 284(1):307-11. PubMed ID: 9435192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data.
    Giardina WJ; Williams M
    CNS Drug Rev; 2001; 7(3):305-16. PubMed ID: 11607045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Belluzzi JD; Domino EF; May JM; Bankiewicz KS; McAfee DA
    Mov Disord; 1994 Mar; 9(2):147-54. PubMed ID: 7910948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ; Shiosaki K; Britton DR
    Eur J Pharmacol; 1996 Aug; 309(1):13-20. PubMed ID: 8864687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
    Domino EF; Ni L
    Eur J Pharmacol; 2008 Dec; 599(1-3):81-5. PubMed ID: 18851961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M; Wright S; Lloyd GK
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
    Fenu S; Espa E; Pisanu A; Di Chiara G
    Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
    Kuno S
    Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
    Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
    Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.